Natera Inc at Stephens Investment Conference Transcript
We'll go and get started here. Thanks, everyone, for joining us on Mason care (inaudible), I'm the diagnostics and in genomics analyst at Stephens today. We have Mike Brophy of Natera with us. Mike, thanks for joining us.
(inaudible).
Questions & Answers
If at any point, anyone in the audience has a question, just feel free to jump in and ask. Maybe we'll kick it off with the quarter. You guys beat on the top line, made additional progress on gross margin had a pretty significant step down in cash burn. You've called out a number of COGS projects in recent quarters. Could you just talk about what has driven the margin improvement recently? What COGS projects are you benefiting from? And maybe what projects are still ahead that could benefit 2024?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
